Rescheduling, Legalization Prospects Top CBT's Most-Read Articles in January

With a new year comes new hope for advancing cannabis reform throughout the U.S., and our readers at Cannabis Business Times know this all too well.

Topping the list of CBT’s most-read articles this month was our team’s annual legalization forecast: 11 States That Could Legalize Cannabis in 2024. Will they? Won’t they? It’s difficult to predict how exactly political momentum will unfold for some of our nation’s last holdouts on the reform front in 2024, but our team remains as hopeful as ever. Notably, voters in four states could potentially decide legalization matters for themselves in November.

Aside from the state-by-state patchwork, 2024 could be pivotal on the federal level should the Drug Enforcement Administration (DEA) reclassify cannabis as a Schedule III drug. And we now know that Schedule III is indeed the actual recommendation from the U.S. Department of Health and Human Services thanks to the fine reporting of Editor-In-Chief Michelle Simakis, who contributed a pair of Top-10 articles on this subject this month.

Also related to rescheduling, cannabis attorney Shane Pennington’s perspective on the DEA’s potential timeline for a decision via an exclusive interview with Senior Digital Editor Melissa Schiller caught the attention of thousands of CBT readers, paving way for our No. 2 most-read article this month.

Among other articles CBT readers engaged with most this month were those that covered the trending topics of how much an ounce of flower cost in 2023; the top 10 best-selling flower strains in California in 2023; and five cannabis policy reform efforts to watch in 2024.

Catch up on all the top 10 most-read articles below: